Microfragmented adipose tissue as a drug delivery system for liver cancer therapy
Microfragmented adipose tissue loaded with paclitaxel provides a localized drug delivery system for liver cancer, effectively inhibiting tumor growth and reducing systemic toxicity by enhancing drug availability at the tumor site.
Patent Information
- Application Number
- JP2024525836
- Authority / Receiving Office
- JP · JP
- Patent Type
- Applications
- Current Assignee / Owner
- Priority Date
- 2021-10-26
- Filing Date
- 2022-10-21
- Publication Date
- 2024-11-13
AI Technical Summary
Liver cancer, particularly hepatocellular carcinoma (HCC), is poorly treated by intravenous chemotherapy due to insufficient drug availability at the tumor site, leading to systemic toxicity and limited treatment options.
The use of microfragmented adipose tissue (MFAT) and its devitalized counterpart (DMFAT) loaded with anticancer agents, such as paclitaxel (PTX), for localized delivery to liver cancer sites, providing a natural scaffold for drug absorption and release.
MFAT and DMFAT effectively inhibit liver cancer cell proliferation in vitro and in vivo, demonstrating significant tumor growth inhibition and apoptosis, with a single administration delaying tumor recurrence and reducing systemic toxicity.
Smart Images

Figure 2024542042000007 
Figure 2024542042000008 
Figure 2024542042000009
Abstract
Description
[Technical field]
[0001] Liver cancer, i.e., hepatocellular carcinoma (HCC), benefits poorly from intravenous chemotherapy due to poor drug availability at the tumor site. The present invention demonstrates the efficacy of human microfragmented adipose tissue (MFAT) and its devitalized counterpart (DMFAT) loaded with suitable anticancer drugs for use in the treatment of liver cancer, i.e., hepatocellular carcinoma (HCC). [Background technology]
[0002] Hepatocellular carcinoma (HCC) is one of the leading cancers worldwide, and despite recent improvements in treatment options, the prognosis remains poor (1). Many factors contribute to the well-known dismal overall survival, including the low proportion of patients suitable for curative treatment due to concurrent chronic liver disease and the high recurrence rate observed after any treatment (2, 3, 4, 5). To date, there is no clearly defined and accepted planned procedure to prevent tumor recurrence. Among the possible treatment strategies, systemic therapy has been widely implemented and investigated, but is typically characterized by low efficacy due to the inability to reach effective concentrations of anticancer drugs specifically at the tumor site due to systemic toxicity. For example, multikinase inhibitors (i.e., sorafenib) can only be used with severe limitations in a limited group of patients. For this reason, the development of strategies to enhance the delivery and specific localization of chemotherapeutic agents to the tumor site would be welcome. Therapeutic approaches to enhance the localization of chemotherapy at the tumor site and reduce systemic toxicity are being studied in detail.
[0003] In previous studies, the inventors discovered that adipose tissue (AT), after the process of adipose microfragmentation (MFAT), becomes a natural scaffold capable of delivering anticancer drugs (6). More specifically, they discovered that the device "Lipogems®" and, surprisingly, the fresh preparation of MFAT specimens through a specific process carried out by its inactivated MFAT (DMFAT) counterpart, are highly effective in absorbing and releasing large amounts of chemotherapeutic agents as the anticancer molecule paclitaxel (PTX). Both MFAT and DMFAT loaded with PTX (MFAT-PTX; DMFAT-PTX) can kill many different human cancer cell lines in vitro when located in the vicinity of tumor cells, and the long-lasting anticancer activity was impressed. In addition, in vivo experiments focusing on DMFAT-PTX activity showed that local application of DMFAT-PTX prevented or delayed tumor recurrence in nude mice orthotopically implanted with neuroblastoma (NB) cells and undergoing surgical resection of the tumor (6). These results demonstrate for the first time that DMFAT could be a highly innovative natural biomaterial capable of localizing and releasing anticancer molecules at tumor sites. Such a drug delivery approach, which can selectively deliver therapeutic agents to tumor sites, shows great potential in cancer treatment as a tool to overcome the limitations of traditional chemotherapy. Although numerous preclinical studies have been published, no targeted drug delivery system for HCC has been fabricated for practical clinical use.
[0004] Based on such observations, since a rational targeted drug delivery system should take into account cancer-specific characteristics, the present inventors studied the characteristics of HCC with the aim of understanding whether MFAT and DMFAT systems could be a meaningful platform for the development of HCC targeted therapy. Thus, in the present invention, the extremely high anticancer activity of DMFAT-PTX against fully developed HCC primary tumors was discovered in in vitro and in vivo models. Furthermore, the present inventors investigated whether a single administration of DMFAT-PTX located near the tumor mass could be sufficient to inhibit or delay tumor growth, and quantified and evaluated the length of the final antitumor effect. The present invention demonstrates for the first time that both fresh MFAT and its inactivated counterpart DMFAT (loaded with PTX) are highly effective in inhibiting the proliferation of the HCC tumor cell line Hep-3B in vitro. In vivo experiments revealed that a single administration of DMFAT-PTX located near the HCC tumor site produced a strong proliferation inhibitory effect on tumor cells. [Prior art documents] [Patent documents]
[0005] [Patent Document 1] International Publication No. 2018 / 193413 Brochure [Patent Document 2] International Publication No. 2011 / 145075 Brochure Summary of the Invention [Problem to be solved by the invention]
[0006] Thus, the present invention demonstrates for the first time that both fresh MFAT and PTX-loaded DMFAT are highly effective in inhibiting the proliferation of hepatoma cells in vitro, and that in vivo DMFAT-PTX placed in situ blocks HCC at an advanced stage of proliferation, suggesting that it serves as a novel, potent and viable delivery drug system for highly aggressive cancers. DMFAT may be a powerful and effective new tool for local chemotherapy of advanced stage HCC, suggesting that it may also be potentially effective in other human liver cancers. This is particularly relevant since HCC benefits poorly from intravenous chemotherapy due to poor drug availability at the tumor site. Starting from evidence showing that human MFAT and its devitalized counterpart DMFAT are effective natural scaffolds for delivering paclitaxel (PTX) to tumors and affecting cancer proliferation in both in vitro and in vivo studies, the present invention demonstrates the efficacy of DMFAT-PTX in well-established HCC in nude mice. [Means for solving the problem]
[0007] Here, paclitaxel-loaded preparations of human microfragmented adipose tissue (MFAT) and its devitalized counterpart (DMFAT) (MFAT-PTX and DMFAT-PTX) were evaluated for anticancer activity in 2D and 3D assays with Hep-3B tumor cells. The efficacy of DMFAT-PTX was evaluated in mice by assessing tumor volume, apoptosis rate, and pharmacokinetics after a single subcutaneous injection near Hep-3B proliferating tumors.
[0008] Potent antiproliferative activity was observed in both 2D and 3D in vitro studies. Mice treated with DMFAT-PTX (10 mg / kg) showed potent inhibition of Hep-3B growth, with 33% complete tumor regression. All treated animals developed tumor ulcers at the site of DMFAT-PTX injection, which healed spontaneously. At a lower drug concentration (5 mg / kg), ulcer formation was prevented while maintaining a statistically significant efficacy against Hep-3B growth. Histology revealed a higher number of apoptotic cancer cells within the tumor, suggesting a prolonged presence of PTX, confirmed by pharmacokinetic analysis of drug diffusion from adipose tissue to cancer cells.
[0009] Accordingly, an object of the present invention is a tissue-based drug delivery system or composition for use in the treatment and / or prevention of liver cancer, preferably hepatocellular carcinoma, comprising: - Microfragmented adipose tissue (MFAT), preferably comprising clusters of adipose tissue having a size in the range of 10 to 5000 μm, preferably 100 to 3000 μm, more preferably 200 to 2500 μm, even more preferably 30 to 1500 μm, more preferably 400 to 900 μm; and - At least one anticancer drug A tissue-based drug delivery system or composition comprising:
[0010] In a preferred embodiment of the tissue-based drug delivery system, the MFAT is devitalized microfragmented adipose tissue (DMFAT).
[0011] Preferably, the adipose tissue is isolated from a mammal, more preferably from a human, said human being being alive or dead; further preferably, said adipose tissue is of autologous or xenogeneic origin.
[0012] In a preferred embodiment of the present invention, the tissue-based drug delivery system is administered to administer, as an anticancer drug, a taxane, preferably paclitaxel or docetaxel, lenvatenib, gemcitabine, mitomycin C, vinorelbine, vincristine, vinblastine, nocodazole, epothilone, navelbine, epidipodophyllotoxin, preferably teniposide, actinomycin, amsacrine, anthracycline, bleomycin, busulfan, camptothecin, carboplatin, chlorambucil, cisplatin, cyclophosphamide, cytoxan, dactinomycin, daunorubicin, doxorubicin, epirubicin, , hexamethylmelamine oxaliplatin, ifosfamide, melphalan, merchlorthamine, mitomycin, mitoxantrone, nitrosourea, plicamycin, procarbazine, triethylenethiophosphoramide, etoposide (VP16), adriamycin, amsacrine, camptothecin, daunorubicin, dactinomycin, doxorubicin, eniposide, epirubicin, idarubicin, irinotecan (CPT-11) and mitoxantrone, pemetrexed, 5-fluorouracil (5-FU), methotrexate, cyclophosphamide, bortezomib, tomozolomide, sorafenib, or any combination thereof.
[0013] Preferably, the anticancer drug is - A combination of sorafenib and paclitaxel; or - a combination of cyclophosphamide and paclitaxel; or - Adriamycin and Paclitaxel combination It is.
[0014] Even more preferably, the anti-cancer drug is paclitaxel or a derivative thereof.
[0015] More preferably, in the tissue-based drug delivery system of the present invention, the amount of the anticancer drug is in the range of 0.1 to 1 mg per ml of MFAT or DMFAT, or 0.001 to 1 mg per ml of MFAT or DMFAT.
[0016] According to a further preferred embodiment, the amount of paclitaxel or its derivatives (preferably docetaxel) to obtain anti-cancer effect / activity is 150 ng or more per 100 μl MFAT or DMFAT and / or 300 ng or more per 100 μl MFAT or DMFAT. Nevertheless, the amount of anti-cancer drug that can be maximally loaded depends on the lipophilicity / hydrophilicity of said drug and its solubility in the MFAT or DMFAT sample. Preferably, the anti-cancer drug can be loaded into the MFAT or DMFAT sample up to the relative saturation point.
[0017] In a preferred embodiment, the tissue-based drug delivery system of the present invention is injected locally into a tumor tissue site and releases a therapeutically effective amount of an anti-cancer drug in situ.
[0018] As indicated above, the tissue-based drug delivery system of the present invention is for use in the treatment and / or prevention of liver cancer, preferably hepatocellular carcinoma, preferably wherein said cancer is primary liver cancer or metastatic liver cancer, preferably primary or metastatic hepatocellular carcinoma.
[0019] A further object of the present invention is the tissue-based drug delivery system of the present invention in combination with an additional therapeutic treatment.
[0020] A further object of the present invention is a pharmaceutical formulation comprising the tissue-based drug delivery system according to any one of the preceding claims and a pharma- ceutically acceptable vehicle or excipient, preferably said pharmaceutical formulation for use in the treatment and / or prevention of liver cancer, preferably hepatocellular carcinoma.
[0021] The tissue-based drug delivery system of the present invention is based on microfragmented adipose tissue, as described in more detail below.
[0022] As used herein, the term "tissue-based drug delivery system" refers to a composition comprising the microfragmented adipose tissue disclosed herein and at least one anti-cancer agent. Preferably, the composition also comprises saline.
[0023] Therefore, in the context of the present invention, microfragmented adipose tissue (MFAT) is used as a scaffold (delivery system) to deliver large amounts of anti-cancer drugs (e.g., paclitaxel (PTX) or sorafenib, or any related derivatives) to cancer cells in the treatment of hepatocellular carcinoma.
[0024] The present invention further demonstrates that in the context of liver cancer treatment, inactivated MFAT (i.e., DMFAT) is highly effective in absorbing and delivering anticancer molecules. The DMFAT can be obtained according to a published procedure (6) based on a freeze / thaw process.
[0025] The tissue-based system of the present invention allows for the administration of molecules and / or drugs to an individual (any animal) in need thereof, with the molecule / drug being delivered to the tumor site.
[0026] In the context of the present invention, fat tissue means adipose tissue, preferably isolated from any animal, more preferably from a human, said human being being alive or dead.
[0027] Preferably, said adipose tissue is isolated (purified) from any part of the body, preferably from the lower abdominal region and / or the flank region. Preferably, said adipose tissue is isolated from the body by a lipoaspiration / liposuction (aspirated fat tissue) procedure. Thus, according to a preferred embodiment, the adipose tissue is lipoaspiration (LASP) or a derivative thereof. In the context of the present invention, lipoaspiration or liposuction or simply lipo means the removal of adipose tissue (fat) under negative pressure conditions, generally by using a cannula.
[0028] As already mentioned above, the adipose tissue (preferably aspirated lipoprotein) is microfragmented (LPG in the Examples and Figures as an example of microfragmented adipose tissue). Preferably, the adipose tissue is microfragmented by a non-enzymatic procedure, therefore the fat of the present invention is more preferably a non-enzymatic microfragmented fat. In other words, the fat used / administered in the present invention as a delivery system is microfragmented without any enzymatic treatment.
[0029] According to the present invention, microfragmented adipose tissue is obtained by using the innovative process disclosed in WO 2018 / 193413, also implemented by the Lipogems device, and more preferably according to the procedure fully disclosed in WO 2011 / 145075.
[0030] Adipose tissue (preferably aspirated fat tissue) is introduced into the Lipogems® device where the adipose tissue is gradually reduced (fragmented) into small clusters of adipose tissue, preferably by gentle mechanical forces, more preferably in the presence of a solution (preferably saline).
[0031] According to a preferred embodiment, the microfragmented fat of the present invention comprises clusters of adipose tissue having a size preferably in the range of 10-5000 μm, more preferably 100-3000 μm, even more preferably 200-2500 μm, more preferably 300-1500 μm, more preferably 200-900 μm, more preferably 200-800 μm, more preferably 400-900 μm.
[0032] According to a further preferred embodiment, the fat, preferably the microfragmented fat or the clusters of microfragmented fat, comprises mesenchymal stem cells (MSCs), and / or adipose derived stem cells (ASCs), and / or adipose stem cells, and / or pericytes, and / or adipocytes, and / or endothelial cells. In this regard, microfragmented fat clusters are particularly advantageous, since they maintain the natural / intact stromal vascular niche of the resident cells and are therefore supported by a stroma that resembles the natural / physiological situation in terms of nutrition and / or signaling. Thus, the stroma provides an environment during the implantation of the cells that is protected from any physical and / or chemical damage, such as mechanical, oxygen, etc. The fragmentation of the fat inside the device is preferably controlled using one or more fragmentation / disaggregation / emulsification means. According to a preferred embodiment, said means are metal means, more preferably metal beads and / or a filter / net, which preferably provides microfragmentation of the tissue sample, the beads moving freely within the device to facilitate separation between the solid and liquid parts of the tissue sample, providing an emulsion of the liquid part (essentially) containing the washing liquid. Preferably, the beads have a size (average diameter) preferably in the range of 0.1-30 mm, more preferably 1-20 mm, even more preferably 5-10 mm, even more preferably 7.5-8.5 mm, and / or said filter / net has an average diameter in the range of 2000 μm-200 μm, preferably 1500 μm-500 μm.
[0033] The average mesh diameter (pore size) of the filter / net is in the range of 50 μm to 6000 μm, preferably 500 μm to 3000 μm.
[0034] It is desirable to effect a gentle movement of the fragmentation / disaggregation / emulsification means throughout the adipose tissue, and more preferably, this movement is effected by performing a controlled shaking of the device.
[0035] According to a preferred embodiment, the fragmentation / disaggregation / emulsification is performed submerged, preferably by a continuous flow of saline buffer through the device, which allows easy washing of the tissue sample (especially effective removal of oil and / or blood residues). More preferably, the fragmentation / disaggregation / emulsification is performed by washing the tissue sample through a continuous flow of saline buffer, which, together with the shaking of the beads, allows the solid material to rise towards the inlet of the saline buffer, leaving the oil and / or blood residues behind and flowing towards the outlet together with the saline.
[0036] The fragmentation / deagglomeration / emulsification procedure preferably lasts for a few seconds.
[0037] Thus, the microfragmented fat of the present invention is obtained by using gentle, enzyme-free, sterile, intraoperative and rapid procedures.
[0038] The adipose tissue of the present invention is preferably isolated from any animal, more preferably from a human. Preferably, said animal / human is healthy or cadaveric. According to a preferred embodiment, the fat is animal adipose tissue, more preferably human adipose tissue, more preferably isolated / aspirated from the lower abdominal and / or flank region of an individual. However, said fat may be isolated from any useful body area. Preferably, the microfragmented fat is of autologous or xenogeneic origin.
[0039] In the context of the present invention, the molecule to be delivered refers to any drug and / or prodrug or therapeutic agent used in the treatment of liver cancer or hepatocellular carcinoma. Preferably, said molecule is lipophilic (poorly water-soluble or water-insoluble).
[0040] However, the tissue-based system of the present invention is also suitable for delivering hydrophilic molecules / drugs. For the purposes of the present invention, the preferred molecules to be delivered are anti-cancer molecules (chemotherapeutic agents), preferably selected from natural products, preferably vinca alkaloids, more preferably vinblastine, vincristine and vinorelbine, taxanes, preferably paclitaxel or docetaxel, vincristine, vinblastine, nocodazole, epothilones and navelbine, epidipodophyllotoxin (teniposide), actinomycin, amsacrine, anthracyclines, bleomycin, busulfan, camptothecin, carboplatin, chlorambucil, cisplatin, cyclophosphamide, cytoxan, dactinomycin, daunorubicin, doxorubicin ... The compound is selected from the group consisting of rubicin, epirubicin, hexamethylmelamine oxaliplatin, ifosfamide, melphalan, merchlorethamine, mitomycin, mitoxantrone, nitrosourea, plicamycin, procarbazine, teniposide, triethylenethiophosphoramide and etoposide (VP16), adriamycin, amsacrine, camptothecin, daunorubicin, dactinomycin, doxorubicin, eniposide, epirubicin, etoposide, idarubicin, irinotecan (CPT-11) and mitoxantrone, pemetrexed, 5-FU, rafenib, methotrexate, cyclophosphamide, bortezomib, tomozolomide, sorafenib. Any combination of the molecules reported above should be considered as forming part of the present disclosure.
[0041] More preferably, the molecule is selected from paclitaxel (PTX - Taxol or Onxal) or a derivative thereof, preferably Abraxane and / or docetaxel, doxorubicin or a derivative thereof, preferably adriamycin and / or vincristine, and any combination thereof.
[0042] More preferably, the molecule is sorafenib.
[0043] The anti-cancer molecule may also be delivered in combination with an additional molecule, preferably selected from an antibiotic, an anti-inflammatory substance, a polyclonal or monoclonal antibody, an immunomodulatory molecule, a biologic drug, and combinations thereof.
[0044] The molecules and / or drugs / prodrugs may be modified in any manner, such as by pegylation, or may be associated with a particle (preferably a nanoparticle, such as an albumin nanoparticle).
[0045] The tissue-based delivery system of the present invention, which is loaded / primed with molecules and / or drugs disclosed above, is used for targeted treatment of liver cancer, preferably for treatment of hepatocellular carcinoma.Targeted drug delivery systems that can selectively deliver therapeutic agents to tumor sites are not available for practical clinical use, especially for hepatocellular carcinoma.
[0046] According to a preferred embodiment, the amount of said molecule / drug that can be loaded / primed into the delivery system of the present invention ranges from 0.5-10 mg / ml of adipose tissue.
[0047] According to a further preferred embodiment, the amount of paclitaxel (PTX) or its derivatives, preferably Abraxane, Docetaxel, to obtain anti-cancer effect / activity is 150 ng or more per 100 ul of microfragmented adipose tissue / lipoaspirate tissue (LPG).
[0048] Nevertheless, the maximum amount that can be loaded depends on the lipophilicity and hydrophilicity of the drug.
[0049] The amount of molecule / drug released per day by the delivery system of the present invention is in the range of 10-15% compared to the loading / priming amount, which is the amount used to load microfragmented adipose tissue / lipoaspirate (LPG).
[0050] According to preferred embodiments of the present invention, the tissue-based delivery system is for topical, parenteral, peritoneal, mucosal, dermal, epidermal, subcutaneous, or transdermal administration.
[0051] When the tissue-based delivery system of the present invention is administered to a subject, the dosage and frequency of administration will usually be determined by the prescribing physician according to the age, weight, sex, and response of the individual patient, as well as the volume of the tumor mass and the severity of the patient's symptoms. Preferably, the tissue-based delivery system of the present invention, which contains an active drug concentration of 100-1000 μg / ml in MFAT or DMFAT, is administered to the patient in an amount contained in 5-30 ml, preferably 7-20 ml.
[0052] According to a further preferred embodiment, the tissue-based delivery system of the present invention is finally loaded with the molecules / agents disclosed above and administered / applied in combination with (before / after) radiation therapy and / or surgery. Preferably, the tissue-based delivery system of the present invention is finally loaded with the molecules / agents disclosed above and applied to the area of interest before surgery, for example to reduce the tumor area to be excised and thus reduce the trauma of surgery. The tissue-based delivery system of the present invention is finally loaded with the molecules / agents disclosed above and is preferably administered / applied before and / or after surgery, preferably topically, intraperitoneally, subcutaneously, preferably for the prevention of cancer recurrence, more preferably for metastatic tumors. [Brief description of the drawings]
[0053] [Figure 1]MFAT and DMFAT specimens loaded with various PTX concentrations showed dose-dependent anticancer activity against human Hep-3B cancer cells in vitro. In this figure, Hep-3B cell proliferation activity (expressed as % of control) in the presence of either conditioned medium (CM) (A and B) or co-culture with adipose specimens with transwell inserts (C and D) is reported. Figure 1A reports the antiproliferative activity of CM (24 h culture) from MFAT and DMFAT loaded with various amounts of PTX (4 to 0.05 μg / ml). Figure 1B shows CM of DMFAT and MFAT loaded or not with 2 μg / ml PTX and tested at various dilutions. Experiments were performed in parallel with free PTX addition to establish the PTX equivalent concentration (p-EC). Figure 1C reports the results of transwell co-cultures of MFAT and DMFAT samples (50 μl) loaded with various amounts of PTX (4-0.05 μg / ml), and Figure 1D reports the antiproliferative activity of various doses of MFAT and DMFAT samples loaded with 2 μg / ml PTX, performed in parallel with free PTX addition. Of note, CM and samples recovered from DMFAT pre-stimulated with 0.1 μg / ml PTX were more effective compared to MFAT. Figure columns are the mean ± SD of two separate experiments performed in triplicate. t-test: * indicates p<0.05; ** indicates p<0.01 for CM and samples from control MFAT and DMFAT, respectively. [Diagram 2]Histological analysis of 3D constructs mixed with Hep-3B cells and control and PTX-loaded DMFAT. Hematoxylin and eosin (H&E) staining shows DMFAT with typical adipose tissue structure (A-C). DMFAT appeared looser and more disaggregated in the control (A) and PTX 0.5 mg / ml-loaded groups (B), but remained more compact when loaded with PTX 1 mg / ml (C). Hep-3B cells were evenly distributed in clusters on the DMFAT serving as a matrix scaffold and were better visible at higher magnification (D-F). The apoptotic effect of PTX-loaded DMFAT on Hep-3B cells detected by Hoechst 33342 staining is shown in G-I ((G) control group, (H) 0.5 mg / ml, and (I) PTX 1 mg / ml-treated groups). Chromatin condensation, nuclear fragmentation, and apoptotic bodies are indicated by arrows. Quantification of cell apoptosis was assessed by Annexin V expression and is expressed as % of positive cells relative to total cells recovered with constructs loaded with various PTX concentrations (J) or incubated with DMFAT in the presence of various amounts of Hep-3B (K). Scale bars = 400 μm (A-C), 200 μm (D-F). Scale bars in G-I 200 mm. Figure columns are the mean ± SD of two separate experiments performed in triplicate. t-test: ** indicates p<0.01 versus control DMFAT. [Diagram 3]Figure 1 shows that a single local injection of DMFAT-PTX inhibited Hep-3b growth in vivo. Approximately 5x106 Hep-3B were injected sc into nude mice. After 10-12 days, when tumors were palpable (diameter 0.5-0.7 cm, body weight approximately 100-200 mg), mice were injected at the tumor site with 200μl saline (A), 200μg / 200μl PTX (10mg / kg) (B), 200μl control DMFAT (C), 200ul / 200ug DMFAT-PTX (D), and 200ul / 100ug DMFAT-PTX (E). Tumor volumes were calculated by measuring tumor diameters every 2 days with a calibrator using the formula 1 / 6πd3. Graphs show tumor growth for each individual animal. In (F) the average tumor growth of the control and treatment groups is shown. Note that a single injection of DMFAT-PTX at a high dose (200 μg / 200 μl) significantly delayed tumor growth; at day 60, 33% of the mice were tumor-free (D). Reducing the PTX concentration in DMFAT to 100 μg / 200 μl still resulted in significant tumor growth inhibition (F). At the time of sacrifice, tumors were weighed; **p<0.01 vs. saline control or DMFAT and free PTX treated mice. [Figure 4] Figure 1 shows immunohistochemical staining of typical biomarkers of HCC. DMFAT-control and PTX samples showed significant diffuse positive reactivity for anti-Epato, arginase, and ck-pan markers, similar to the control group. DMFAT-PTX showed decreased anti-Epato and arginase positivity and increased CK-Pan expression at both doses used (images shown in figure refer to 100μg / 200μl dose). Photographs were taken at 10x magnification. [Diagram 5]Figure 5D shows that DMFAT-PTX treatment inhibited the proliferation marker expression MIB-1 / Ki67 in Hep-3B tumors. Nuclear staining of the proliferation marker Ki67 is shown in mice treated with control group (A), DMFAT (B), PTX 10 mg / kg (C), DMFAT-PTX 10 mg / Kg (D), and DMFAT-PTX 5 mg / kg (E). A higher percentage of positive Ki67 expression was observed in the control and DMFAT groups. In the DMFAT-PTX-treated groups, this percentage was significantly reduced, especially with DMFAT-PTX 10 mg / Kg. Some significant inhibition was also observed in the free PTX-treated group. Figure 5F reports the quantification of positive Ki67 cells in each group. Numbers represent the positive cells counted and represent the mean ± SD of 10 different fields (magnification ×20). t-test: * indicates p<0.05 vs. control; ** indicates p<0.01 vs. control. [Figure 6]Figure 6 shows the PK of PTX released by DMFAT-PTX in normal and tumor-bearing mice. Figures 6A and B show the blood levels of PTX released by sc-administered DMFAT-PTX (5 mg / kg) in normal and tumor-bearing mice, detected at 2, 24, 72, and 168 hours after injection, respectively. As expected, the plasma levels of PTX after sc treatment dropped rapidly, but were detectable up to day 7 in normal mice (A), whereas in tumor-bearing mice, PTX was only detectable up to 24 hours, suggesting a more rapid clearance of the drug from the bloodstream (B). Figure 6C shows the residual drug levels at the site of sc injection in normal mice. Notably, at 2 hours, the residual amount of PTX found in situ was about 40% of that injected, whereas after 168 hours, a significant amount of drug was still detected in the residual DMFAT samples (up to 1 μg / g), which must be considered pharmacologically significant. In (D) the PTX concentration in both the residual DMFAT and tumor samples is shown. After 2 h, in situ PTX was only 17% of the injected amount, but was undetectable in the tumor. Detection of PTX in the tumor began at 24 h, reached a concentration equal to that of the adjacent DMFAT at 48 h, and maintained a similar concentration up to 168 h. However, at this time point, the drug present in the residual DMFAT and tumor samples (0.2 μg / g in DMFAT and 0.3 μg / g in tumor) was lower compared to the drug recovered in normal mice, but still higher compared to the IC50 of PTX. In (E) the kinetics of PTX detected in both DMFAT and tumor samples is shown. In (F) an overview of the values of PTX concentration (expressed as μg / g tissue) at various time points during DMFAT implantation is given. Numbers in the figure are mean ± (maximum 1 μg / g) SD. [Figure 7]Figure 1 shows that PTX showed anti-proliferative activity on Hep-3B cells in culture. In (A), PTX at various concentrations from 0.1 to 1000 ng / ml was added to cultured Hep-3B cells. After 72 hours of incubation, cells were detached and counted. PTX showed an IC50 of 15±3 ng / ml and an IC90 of 25±8 ng / ml. In (B), photographs (10x magnification) of Hep-3B cells cultured in the presence of PTX showing strong growth inhibition at concentrations up to 25 ng / ml are reported. Figure columns are % of proliferation relative to control medium and are the mean ± SD of three separate experiments performed in triplicate. t-test: * and ** indicate p<0.05 and p<0.01, respectively. [Figure 8] Figure 1 shows the effect of DMFAT-PTX-CM on Hep-3B proliferation. Representative images of Hep-3B cancer cell cultures stained with 0.25% crystal violet at 72 hours of treatment with CM (1:2 dilution) from control DMFAT (A), DMFAT-PTX (0.25 μg / ml) (B), DMFAT-PTX (0.5 μg / ml) (C), and DMFAT-PTX (1 μg / ml) (D). The pictures (10x magnification) show the potent anticancer activity of CM from DMFAT-PTX. [Figure 9] Figure 1 shows the effect of DMFAT-PTX samples (50 μl) placed in the upper well of a transwell insert. Hep-3B are shown seeded in the lower well of a transwell insert and stained with 0.25% crystal violet solution after 72 hours of incubation. Photographs (10x magnification) show the effect of control DMFAT (A), DMFAT-PTX (0.25 μ / ml) (B), DMFAT-PTX (0.5 μg / ml) (C), and DMFAT-PTX (1 μg / ml) (D) samples on Hep-3B. In the high magnification box (40x), the presence of cells with apoptotic features is indicated by block arrows. [Figure 10]Immunohistochemical characterization of Hep-3B-induced HCC in mice. H&E staining revealed angiogenic tumors containing pleomorphic cells (A), centrally vacuolated nuclei, and prominent nucleoli with some pleomorphic and multinucleated giant cells, more easily visible at higher magnification (B and C). Immunohistochemical staining confirmed the hepatic origin of the tumor (10x magnification). Cells showed distinct granular cytoplasmic staining for anti-Epato (D) and moderate to strong diffuse reactivity for Arginase-1 (E). Pan-CK marker was present in the majority of Hep-3B cells and showed distinct cytoplasmic staining reaction with membrane highlighting (F). [Figure 11] Representative photographs of mice injected with Hep-3B cells in the right flank and treated with DMFAT loaded or not loaded with PTX. (A) shows a control tumor nodule 10 days after Hep-3B injection, (B) shows a saline-treated control mouse with a large tumor (diameter >2 cm) on day 32 (just before sacrifice). Panel (C) shows a tumor on day 12 after local injection of free PTX. (D) and (E) show two different mice with DMFAT (200 μl) located immediately next to the tumor nodule, and (F) shows a case of a tumor treated with DMFAT-PTX (5 mg / kg) on day 31. Note the relatively small size of the tumor and the absence of skin ulcers. [Figure 12] Local injection of DMFAT-PTX (200 μg / 200 ul) induced regression of Hep-3B but also cutaneous lesions, which healed spontaneously. Photographs of mice injected with Hep-3B cells in the right flank and then treated locally with DMFAT-PTX (10 mg / kg) taken at various time intervals: 5 days (A), 9 days (B), 13 days (C), 17 days (D), 21 days (E), and 25 days (F) after treatment, respectively. Notably, all lesions healed spontaneously in about 2-3 weeks without the need for any specific pharmacological treatment. Block arrows indicate the tumor and the area of DMFAT-PTX injection. [Figure 13]Skin histology of mice (90 days) with HCC tumors at the time of healing. H&E staining of skin sections revealed no observable damage to the mouse skin after wound healing in specimens treated with DMFAT-PTX 200. The epidermal layer containing the stratum corneum (A), the dermis containing glands and blood vessels (B), and the subcutaneous tissue containing adipocytes and skeletal muscle are visible (C). In (D), an image is presented at 4x magnification showing infiltration of the interstitial areas by lymphocytes; at higher magnifications (10x (E) and 20x (F)), foreign body cells (arrows) and reactive lymphoid cells (black arrows) are easily seen. [Figure 14] Histopathological analysis of HCC tumors induced by Hep-3b cells treated with DMFAT. In (A), necrotic areas characterized by foci of cells with eosinophilic cytoplasm and pyknotic or karyorrhexis nuclei in HCC are reported. DMFAT-treated tumor masses were characterized by strong fatty degeneration with widespread distribution of lipid droplets (B). At higher magnification, fatty necrotic areas with infiltration of inflammatory cells, mainly neutrophils around fatty vacuoles, could be detected (C, D). DETAILED DESCRIPTION OF THE PREFERRED EMBODIMENTS
[0054] Materials and Methods Sample collection, ethical statement, MFAT and DMFAT preparation Lipoaspirate (LP) samples were obtained by liposuction of subcutaneous tissue using a disposable cannula provided with the Lipogems® kit as previously described elsewhere (7, 8). Tissue samples were obtained from plastic surgery procedures after signed informed consent by the patients, in accordance with the Declaration of Helsinki. Approval for their use was obtained from the Institutional Ethical Committee of Milan University (n.59 / 15, CE UNIMI, 09.1115). For all in vitro and in vivo experiments performed in this study, adipose tissue was obtained from five different human donors undergoing plastic surgery. MFAT specimens were obtained as previously described (7, 9). Briefly, using a standard 225 ml Lipogems® device (provided by Lipogems® International, Milan, Italy), LP collected with a syringe was forced through a filter into the Lipogems® device for initial cluster reduction, and complete disaggregation was obtained by shaking the device with five stainless steel marbles inside. The microfragmented adipose tissue was then aspirated with a syringe connected to the device and ready for the experiment. Devitalized MFAT (DMFAT) was prepared according to previously published procedures (6, 10) consisting of three freeze (-20°C) and thaw (F / T) cycles. Briefly, aliquots (5 ml) of MFAT were transferred to conical tubes and washed three times with PBS by centrifugation at 200 g × 10 min. After discarding the PBS washing solution, the MFAT was subjected to freeze (-20°C) and thaw (F / T) cycles (usually 3 times for 30 min each) leading to the death of all cells in the stromal vascular fraction (SVF). Aliquots (1-2 ml) of DMFAT were stored at -80°C until use in experiments, while others were analyzed to confirm the lack of cell vitality by SVF extraction with collagenase (SIGMA, St. Louis, Mo, USA) (0.2 w / v%) after processing the final cell pellet by trypan blue assay.It should be noted that DMFAT samples prior to use in in vitro and in vivo experiments were washed several times with PBS by centrifugation to remove as much as possible the total cell debris and residual presence of membrane proteins and genetic material contents, and then examined as previously described (10).
[0055] Chemicals and Reagents Methanol, isopropanol, acetonitrile, and formic acid (all analytical grade) were supplied by Merck (Darmstadt, Germany). Ammonium formate was purchased from Sigma Aldrich (St. Louis, MO, USA). Water was MilliQ grade. Paclitaxel (PTX) and PTX-D5 were purchased from Cabru (Arcore, Italy). A clinical formulation of PTX (6 mg / ml stock solution, Fresenius Kabi, Italy) was used to process the fat samples.
[0056] Tumor cell lines The in vitro and in vivo anticancer activity of PTX loaded in MFAT and DMFAT was evaluated in the HCC cell line Hep-3B. This cell line was kindly provided by Dr. Valentina Fonsato (Molecular Biotechnology Center (MBC), University of Turin, Turin Italy) and purchased from ATCC (ATCC® HB-8064™). Hep-3B was maintained according to the ATCC instructions. Briefly, cells were cultured in Eagle's Minimum Essential Medium (MEM) (Euroclone, UK) supplemented with 10% fetal calf serum FCS (Gibco, Life Technologies, Monza, Italy) and passaged weekly at a ratio of 1:5.
[0057] Procedure for PTX pre-stimulation of MFAT and DMFAT samples for in vitro experiments MFAT and DMFAT samples were pre-stimulated with PTX according to published procedures (6). Briefly, after washing with phosphate-buffered saline (PBS) by centrifugation (200 g × 10 min), approximately 1 ml of MFAT and DMFAT samples was mixed with various concentrations of PTX (ranging from 0.05 to 4 μg / ml), freshly prepared from a 6 mg / ml stock solution and diluted in MEM + 0.2% bovine serum albumin (BSA). Samples were then shaken and incubated for approximately 30 min (at 37 °C, 5% CO2). At the end of the incubation, MFAT-PTX and DMFAT-PTX samples were washed twice with PBS (200 g × 10 min) to remove unbound PTX. Control untreated MFAT and DMFAT samples were treated similarly. At this point, both primed and non-primed MFAT and DMFAT samples were considered ready to be studied for biological activity in vitro.
[0058] Assessment of the activity of PTX-loaded MFAT and DMFAT on Hep-3B proliferation in a 2D assay MFAT-PTX and DMFAT-PTX preparations were evaluated for anti-cancer activity either using transwell inserts in co-culture assays with Hep-3B cells or by evaluating the anti-proliferative activity of conditioned medium (CM) obtained by incubating approximately 1 ml of MFAT-PTX and DMFAT-PTX specimens (loaded with various PTX concentrations ranging from 0.05 to 4 ug / ml) cultured in similar volumes of MEM complete medium for 24 hours (37°C, 5% CO2).
[0059] The direct anticancer activity of MFAT-PTX or DMFAT-PTX samples was tested using transwell inserts (pore size 0.4 μm; BD Falcon, NJ, USA). 4Hep-3B cells were seeded in wells (24-multiwell plates), then covered with 700 μl / well of complete MEM medium and allowed to adhere for 3 h. Next, various amounts (50, 25, and 12.5 μl) of MFAT-PTX, DMFAT-PTX, or control untreated specimens were placed in the upper compartment of the transwell insert, covered with 200 μl of medium, and then placed in the wells together with the cancer cells. After 72 h of incubation, the Hep-3B in the wells were detached and counted, or, in a more limited set of experiments, the direct effect of the adipose specimens on tumor cell proliferation was evaluated by staining the attached Hep-3B cells with 0.25% crystal violet (Sigma Aldrich, USA) and evaluating the optical density of the eluted dye obtained upon cell lysis (6).
[0060] The anticancer activity of CM derived from both MFAT-PTX or DMFAT-PTX samples was assessed in a 72-h proliferation assay as previously described (6, 11). 4 Hep-3B cells were seeded in wells (24 multiwell plates), then covered with 500 μl / well of complete MEM medium and allowed to adhere for 3 h. CM from cultured MFAT-PTX, DMFAT-PTX, and control untreated specimens at various dilutions (1:2 to 1:10) were then added to the wells and further incubated for 72 h. At the end of the incubation, cancer cells were detached with trypsin and counted as previously described (11). The antitumor activity of MFAT-PTX and DMFAT-PTX-derived CM was compared to that of pure PTX and expressed as PTX equivalent concentration (p-EC) according to the following algorithm: p-EC (ng / ml) = IC 50 PTX×100 / V 50 (μl / well) (where, IC 50 PTX is the concentration of pure PTX that produces 50% growth inhibition, and V 50 are the respective amounts of CM that produce the same inhibition).
[0061] The antitumor activity of MFAT-PTX and DMFAT-PTX derived CM was compared to that of pure PTX and expressed as PTX equivalent concentration (p-EC) according to the following algorithm: p-EC (ng / ml) = IC 50 PTX×100 / V 50 (μl / well) (where, IC 50 PTX is the concentration of pure PTX that produces 50% growth inhibition, and V 50 are the respective amounts of CM that produce the same inhibition).
[0062] Histological analysis of DMFAT-Hep3B cells in 3D constructs The efficacy of MFAT-PTX or DMFAT-PTX samples against Hep-3B was also examined in a 3D assay. Briefly, 50 μl of control or PTX-loaded MFAT samples (0.5 at 1 mg / ml) were mixed with 100 μl of Matrigel (BD Biosciences, Franklin Lakes, NJ, USA) at 4°C and incubated with Hep-3B (3 and 5 × 10 6(1000 cells) were added and left to gel for 1 h at 37°C. Completely grown MEM was then added to the gel and further incubated for 72 h. Finally, the medium was removed and the gel was processed for immunocytochemistry analysis by the cytoinclusion technique (12). Samples were fixed in 4% paraformaldehyde (PFA), cryoprotected in 30% (wt / vol) sucrose solution at 4°C overnight, and then embedded and frozen in Tissue-Tek OCT Compound (Tissue-Tek; Sakura Finetek, Torrance, CA, www.sakuraus.com.). Sections were cut at 5 μm thickness in a cryostat at −20°C and stained with hematoxylin and eosin (H&E (Sigma-Aldrich, St. Louis, MO, USA) or Hoechst 33342 (Thermo Fisher Scientific) to detect apoptotic cells. Samples were visualized using conventional light or fluorescence microscopy. In another set of experiments, apoptosis was examined using Annexin V staining (Thermo Fisher Scientific). Briefly, after 72 h of incubation, Hep-3B cells were extracted from the 3D constructs by digestion with collagenase (Sigma). After washing of the cells by centrifugation, a fluorescent Annexin V conjugate was used for flow cytometry (FC) as previously described (6).
[0063] Histology of Hep-3B tumor specimens in vivo All tumor specimens were embedded in 10% formalin and paraffin; sections were stained with hematoxylin and eosin (H&E). After evaluation of conventional H&E staining, 10 white sections were then obtained from each sample and processed for immunohistochemistry (IHC) staining. IHC was performed automatically with Leica Bond Max™ technology (Arginase, CK-PAN, CK7, and ANTI-EPATO) and Ventana Bench Mark Ultra (Ki-67): ANTI-HEPATO: antigen retrieval 30' EDTA, (dil. 1:300 clone OCH1ES Dako-Agilent); ARGINASI: antigen retrieval 30' EDTA, (dil. 1:100 clone SP156 Cell Marque Diapath) KI-67: TQ clone 30-9 Roche-Ventana); CK-PAN: antigen retrieval 5' Enzyma, (dil. 1:200 clone MNF116 Dako Agilent); CK-7: antigen retrieval 15' EDTA, dil. 1:100 clone OV-TL 12 / 20 Dako Agilent. All stained sections were evaluated under a NIKON ECLIPSE E 600 microscope equipped with an OLYMPUS DP21 camera.
[0064] Evaluation of the in vivo antitumor activity of DMFAT-PTX Five-week-old athymic nude Foxn1nu mice were purchased from Envigo (Envigo, Bresso, Italy) and kept under pathogen-free conditions. The experiments were reviewed and approved by the License and Ethics Committee of IZSLER (Istituto Zooprofilattico Sperimentale della Lombardia e dell'Emilia Romagna, Brescia, Italy) and the Italian Ministry of Health. It should be noted that only DMFAT specimens were used in this experiment, due to the advantage of being able to store frozen biomaterials until their use in mice.
[0065] In a preliminary experiment, three mice were inoculated with 5 × 10 6 Hep-3B cells were injected subcutaneously (sc). Mice were observed daily to define the date of tumor appearance, and when the nodule was 1 cm in diameter, the mice were sacrificed, and the tumors were removed and examined by histological examination to confirm the characteristics of HCC. It should be noted that only DMFAT specimens were used in this experiment, due to the advantage that frozen biomaterials could be preserved until use in mice. In the first series of experiments, mice (n=6 / group) were injected with 5×10 6 Hep-3B cells were injected (day 0). Tumors were cultured according to the formula 1 / 6πd 3 Calculated using 65-179mm 3 The tumors were allowed to grow to a mean diameter of 0.5 / 0.7 cm, corresponding to tumor volumes ranging from 0.01 to 0.28 cm (median mass 120 mg) (13). After 10–14 days, mice were randomly divided into four groups and treated with a single injection of 200 μl saline (control group CTRL), DMFAT (200 μl), 10 mg / kg DMFAT-PTX (200 μg / 200 μl), and free PTX drug (200 μg / 200 μl saline) immediately adjacent to the tumor nodule. Loading of PTX into freshly thawed DMFAT samples was performed 20–30 min prior to injection as described above, with 1 mg PTX (approximately 166 μl of 6 mg / ml stock PTX solution) added to 1 ml DMFAT and stirred. After treatment, mice were observed daily; tumor diameters were measured every 2 days using a calibrator. In accordance with ethical protocols, all mice were sacrificed when tumor nodules reached a diameter of 2.0-2.5 cm (body weight ≥ 2 g) or 60 days after implantation regardless of diameter. At this point, only tumor-free mice were followed for 90 days. Animals were euthanized by carbon dioxide inhalation followed by cervical dislocation.
[0066] In a second series of experiments, mice (n=6 / group) were administered 5×10 6 Hep-3B mice were similarly injected sc and treated locally with a half dose of PTX, DMFAT-PTX (100 μg PTX / 200 μl), equivalent to 5 mg / kg.
[0067] Pharmacokinetics (PK) of PTX released by DMFAT-PTX and taken up by tumor nodules In another series of studies, the PK of PTX in cancer cells in the presence of nearby DMFAT-PTX was studied. For this purpose, mice (n=3 groups) were subcutaneously (sc) injected with Hep-3B and, when the tumor mass was palpable, mice were administered 200 μl of DMFAT loaded with 100 μg PTX (5 mg / kg dose) on the lateral side of the tumor. Mice were then sacrificed 2 h, 1, 2, 3, and 7 days after treatment, and blood, tumor nodules, and residual subcutaneous DMFAT-PTX tissue were collected, placed in tubes, and rapidly stored (-80°C) until used for evaluation of PTX content by mass spectrometry. Another group of tumor-free mice received the same sc injection of DMFAT-PTX (same dose of 5 mg / kg PTX) to investigate the release of PTX in the absence of cancer nodules.
[0068] Biological samples consisting of whole blood (100 μl), tumor, and adipose tissue homogenates (1–5 mg) were spiked with 25 μl of IS (paclitaxel D5, PTX-D5 10 μg / ml) and extracted by single-step liquid extraction with methanol / isopropanol (60:40, v / v). Dried extracts were redissolved in 150 μl of acetonitrile / water (1:1, v / v), clarified through a 45 μm filter, and 5 μl was injected for LC-MS / MS analysis. All samples were extracted in duplicate. The LC-MS / MS consisted of a Shimadzu UPLC coupled to a Triple TOF 6600 Sciex (Concord, ON, CA) equipped with a Turbo Spray IonDrive.
[0069] Plasma extraction procedure Extraction and purification from plasma was performed by SPE. 50 μL of plasma was added with 100 μL of IS (PTX D5 0.1 μg / mL) and 850 μL of water, then sonicated for 30 min at 40° C. (Sonorex, Bandelin electronic, Berlin). Samples were centrifuged for 5 min at 10,000 rpm (MiniSpin, Eppendorf, Hamburg). Solid phase extraction was performed with Strata TM-X 33 μm Polymeric Reversed Phase SPE 30 mg / 1 mL extraction cartridges from Phenomenex (Anzola Emilia, Italy) connected to Visiprep Solid Phase Extraction Vacuum Manifolds from Supelco (Bellefonte, USA). Before use, the cartridges were conditioned with 1 ml of methanol and 1 ml of deionized water. Diluted samples were filtered through the cartridges. The cartridge was then rinsed with 1 mL of 5% meOH in deionized water and vacuum dried for 5 min to remove excess water. Finally, the retained compounds were eluted with 1 ml of methanol / isopropanol / formic acid (60:39.2:0.8) and the eluate was collected in a test tube. The eluate was evaporated to dryness by a gentle stream of nitrogen. Finally, the residue was redissolved in 150 μl of acetonitrile and 10 μl was injected for LC-MS / MS analysis.
[0070] Tissue extraction procedure Extraction and purification from the various tissues (sc injection area and tumor samples) were performed by single-step extraction. Weighed tissues (10-50 mg) were homogenized in 100 μl of methanol with a TissueLyser LT (Qiagen, Hilden, Germany) for 3 min at 50 oscillations / s. 100 μl of IS (paclitaxel D5 0.1 μg / mL) and 800 μl of methanol / isopropanol / formic acid (60:39.2:0.8) were added to the samples and then sonicated for 30 min at 40° C. Extracts were evaporated to dryness with a gentle stream of nitrogen. Tissue residues were redissolved in 150 μl of methanol, centrifuged at 10,000 rpm for 10 min, filtered through a NY 0.45 μm filter (LLG labware, Meckenheim), transferred to vials and 10 μl injected for LC-MS / MS analysis.
[0071] LC / MS-MS conditions The analytical system consisted of an HPLC connected to a tandem mass spectrometer. The liquid chromatographic system was a Dionex 3000 UltiMate instrument (Thermo Fisher Scientific, USA) equipped with an autosampler, a binary pump, and a column oven. Separation was performed on a reversed-phase Luna C18(2) 50 mm x 2, 3 μm particle size (Phenomenex, California, USA) analytical column preceded by a security guard cartridge with a linear gradient between eluent A (water + 5 mM ammonium formate + 0.1% formic acid) and eluent B (acetonitrile + 0.1% formic acid). The column was equilibrated at 20% (B) for 2 min, increased to 95% (B) in 4 min, held for 0.5 min, returned to initial conditions in 0.5 min, and held at 20% (B) for 2 min. The flow rate was 0.4 ml / min and the autosampler and column oven were kept at 15 °C and 30 °C, respectively. The tandem mass spectrometer was an AB Sciex 3200 QTRAP instrument (AB Sciex Srl, Milano, Italy) equipped with an electrospray ionization TurboIonSpray™ source. The instrument was controlled according to the proprietary manufacturer's software and manufacturer's instructions. Analytical data were processed using Analyst software (version 1.6.2). The ion spray voltage was set to 5.5 kV and the source temperature was set to 400° C. Nitrogen was used as the nebulizer gas (GS 1, 40 psi), turbospray gas (GS 2, 45 psi), and curtain gas (30 psi). Collision-activated dissociation (CAD) was set to a medium level. The dwell time was set to 0.3 seconds and MS scans were performed in positive ion mode (ESI+). Product ion spectra (MS-MS) were generated with optimized DP to identify prominent product ions of the analytes using nitrogen as the collision gas. Collision energies (CE) of product ion transitions were optimized by CE ramping with direct infusion. Multiple reaction monitoring (MRM) mode was used. In Table 1 the optimal compound-dependent parameters are reported.
[0072] [Table 1]
[0073] Method validation: Linearity and LOQ Linearity was verified by least squares regression line fitting and correlation coefficient (R 2 ) A six-point matrix-matched calibration curve was evaluated by spiking increasing amounts of analyte in blank plasma. The calibration curve was obtained by plotting the ratio of the peak area of the quantification ion of the analyte to the peak area of the quantification ion of the internal standard against the corresponding concentration of the analyte in the concentration range of 0-100 ng / vial. Linearity was observed over the entire range. The correlation coefficient of the calibration curve, R 2 The values of were higher than 0.99. The obtained LOQ value was 0.5 ng / vial calculated by Multiquant software 2.1 with precision of 80-120% and CV% < 20%. Recoveries from various biological matrices by the two extraction methods ranged from 63 to 70.
[0074] statistical analysis Experiments were performed using MFAT and DMFAT samples from a total of five human donors investigated. Tests were usually performed in triplicate and reported data are expressed as mean ± standard deviation (SD). Where necessary, appropriate statistical tests were performed using GraphPad software (GraphPad Inc., SanDiego, CA, USA). Statistical analyses were also performed with Statistical Package for Social Science (SPSS version 13, IBM, NY, USA). Statistical differences were assessed by analysis of variance followed by Tukey-Kramer multiple comparison test and unpaired two-tailed Student's test. p ≤ 0.5 was considered statistically significant.
[0075] result PTX exhibited antiproliferative activity against Hep-3B cell line in vitro Initial experiments were performed to establish the efficacy of PTX in inhibiting Hep-3B proliferation. For this purpose, various concentrations of PTX (0.1 ng / ml to 1000 ng / ml) were added to the culture medium to inhibit Hep-3B proliferation by 50% (IC 50 ) and 90% (IC 90 The doses of PTX required to reduce the IL-10 expression in Hep-3B cells were 15 ± 2 and 25 ± 8 ng / ml, respectively (Fig. 7). Thus, Hep-3B cells displayed a remarkable resistance to the antiproliferative activity of PTX when compared with other cancer cell lines previously tested (6, 14).
[0076] PTX-loaded MFAT and DMFAT samples exerted potent antitumor activity against Hep-3B in vitro The activity of CM derived from control and MFAT or DMFAT loaded with various concentrations of PTX (0.05-4 μg / ml) was examined (Figure 1). CM derived from both cultured MFAT and DMFAT pre-stimulated with 0.25-4.0 μg PTX showed similar potent inhibition of Hep-3B proliferation. However, DMFAT appeared to be more effective compared to MFAT, especially at low doses of PTX (0.1 μg) (Figure 1A). This trend was confirmed by evaluating the p-EC of PTX released into the medium. As shown in Figure 1B, both DMFAT-PTX-CM and MFAT-PTX-CM showed dose-dependent efficacy, with p-EC of 12 ± 2 and 18 ± 5 ng / ml for MFAT and DMFAT, respectively. The morphological appearance of Hep-3B cells treated with DMFAT-PTX-CM is shown in Figure 8.
[0077] The antitumor activity of MFAT-PTX and DMFAT-PTX against Hep-3B was also tested using transwell inserts. A strong inhibition of Hep-3B proliferation was obtained that correlated with increasing amounts of PTX loaded (Figure 1C). No significant differences in efficacy were observed between MFAT-PTX and DMFAT-PTX samples among the various preparations. In addition to a strong reduction in the number of cancer cells, many Hep-3B cells acquired necrotic and apoptotic features upon co-culture with DMFAT-PTX samples (Figure 9).
[0078] Significant inhibition of Hep-3B proliferation was also obtained by reducing the amount of MFAT-PTX and DMFAT-PTX samples (loaded with 2 μg of drug) seeded on the transwell inserts by 1:4 (12.5 ul) (Figure 1D). DMFAT-PTX was potent enough to cause approximately 90% inhibition of Hep-3B proliferation, with a trend towards greater potency compared to MFAT-PTX among the AT preparations.
[0079] 3D Matrigel constructs to test the interaction of Hep-3B cells with DMFAT loaded with or without PTX To mimic the in vivo situation, 3D constructs were prepared by mixing control and DMFAT-PTX with Hep-3B cells and then processed for H&E staining (Figure 2). DMFAT showed typical adipose tissue structure, but it appeared looser and more disaggregated in the control group (Figure 2A) and specimens loaded with PTX 0.5mg / ml (Figure 2B) compared with specimens loaded with the highest dose of PTX 1mg / ml (Figure 2C). At higher magnification, a uniform distribution of Hep-3B cells within the trabecular / cancellous structure of DMFAT specimens could be observed, but no obvious difference was found between control (Figure 2D) and PTX-loaded (Figure 2E, F).
[0080] However, analysis of cancer cell apoptosis detected by Hoechst 33342 staining showed that control DMFAT sections had very few cells (Fig. 2G), whereas all DMFAT-PTX groups had significantly increased cells (Fig. 2H, I). Apoptotic values (chromatin condensation, nuclear fragmentation) were approximately 5-10 times higher compared to those present in control DMFAT. The apoptotic effect of DMFAT-PTX on Hep-3B was also examined by Annexin V expression, which was significantly higher in DMFAT-PTX compared to DMFAT and untreated cells as a control, and was dependent on the PTX dose (Fig. 2J), but not on the increased number of Hep-3B cells placed within the 3D construct (Fig. 2K). Similar results were obtained with fresh MFAT-PTX (data not shown).
[0081] Antitumor effect of DMFAT-PTX in established subcutaneous tumors To verify the HCC nature of the Hep-3B cell line, we inoculated 5 × 10 cells into a small number of mice. 6 Hep-3B cells were injected sc, mice were sacrificed when tumor nodules were palpable, tumors were excised, and analyzed by IHC for expression of HCC markers. All tumor nodules analyzed showed strong cellularity composed of large sized cells with some atypical mitoses. Hepatocellularity was confirmed by scattered strong positivity of immunostaining for anti-human hepatocyte-hepar., arginase, and CK-PAN (Figure 10).
[0082] We then evaluated the potential anticancer activity of a single DMFAT-PTX administration at the tumor site as described in Materials and Methods (Figure 11). With this treatment schedule, control mice grew approximately 2 cm 3 The tumor reached a tumor volume of 2 cm (Figure 3A). Similar tumor growth behavior was observed in mice treated locally with the free drug PTX (Figure 3B) and DMFAT (Figure 3C). In contrast, mice treated with DMFAT-PTX (10 mg / kg) showed a significant delay in tumor growth. Even at the maximum observation period of 60 days, the tumor volume did not reach 2 cm. 3 None of the mice reached a tumor volume of 0.904 ± 0.312 cm, approximately half the volume of controls. 3 and 33% of the mice were tumor-free (Figure 3D). However, by using this high PTX dose, we observed skin lesions with a necrotic appearance in all treated mice. None of the mice died, and such lesions healed spontaneously in all cases, in about 2-3 weeks, without the need for any special pharmacological treatment (Figure 12). Due to this observation, another group of mice was treated with a reduced concentration of DMFAT-PTX down to 5 mg / Kg. At this dose, none of the mice showed skin ulcers at the site of DMFAT-PTX injection, and tumor growth was still significantly delayed, reaching about 2 cm after 58 days. 3After 60 days, 15% of the mice were tumor-free (Figure 3E). The trends of tumor growth in mice from all groups are shown in Figure 3F; Table 1 provides an overview of all the results.
[0083] [Table 2]
[0084] Note: Mice receiving DMFAT-PTX 10mg / Kg had a significant reduction in tumor mass 60 days after injection (**p<0.01), in addition, about 33% of the mice were tumor-free and were sacrificed after 90 days and considered cured. Lower efficacy was observed in mice treated with DMFAT-PTX loaded with half the dose of PTX (5mg / Kg). However, in this group, tumor mass was not significantly reduced compared to the control, although growth was still significantly delayed (**p<0.01 vs. control). In addition, 15% of the mice were tumor-free. No significant effect was observed in groups of mice treated with either DMFAT or PTX alone compared to the control.
[0085] To confirm the absence of tumors in treated mice, surviving animals were sacrificed after 90 days and the tumor inoculation area was examined. Histology of the skin tissue confirmed the absence of any residual neoplastic tissue and revealed normal skin with minimal reactive areas of inflammation (Figure 13).
[0086] Finally, histological examination of tumors of control and treated mice was performed at the time of sacrifice of the mice. IHC showed no significant differences in the expression of HCC markers. CK-PAN, arginase, and anti-liver positive cells were similarly present, and staining was diffuse in control, as well as PTX and DMFAT treated tumors, with the exception of DMFAT-PTX treated mice, which resulted in more focal arginase staining (Figure 4). Interestingly, some residual adipose tissue was still present in tumors of control DMFAT injected mice at the time of sacrifice of the mice. This was not seen in tumors of mice treated with DMFAT-PTX (both doses used), suggesting that PTX primed digestion of xenograft adipose tissue was enhanced (Figure 14).
[0087] By examining and quantifying the Mib-1 / Ki67 proliferation marker index, significant differences were observed. Indeed, a significant decrease in Ki67 expression was observed in tumors of mice treated with DMFAT-PTX at both doses. Notably, in tumors treated with the higher PTX dose, the number of Ki67 positive cells / field was almost 5-fold lower (127±43 vs. 654±123 in the control group). Some decrease in Ki67 expression was also observed in mice treated with the free PTX drug (Figure 5).
[0088] PK of PTX delivered by DMFAT-PTX when located close to tumor nodules The PK of free PTX has been extensively studied elsewhere (15, 16). Here, we focused on investigating the PK of PTX delivered by DMFAT when located in the vicinity of cancer cells (Figure 6). For this purpose, groups of mice were injected with Hep-3B cancer cells and, in case of tumor nodule formation, were locally injected with DMFAT loaded with a reduced dose of PTX 5 mg / kg (corresponding to 100 μg / 200 μl to avoid eventual skin ulceration). A group of control normal mice (no tumor injected) was treated similarly. In these normal mice groups, PTX blood concentrations at 2 h were 200 ± 34 ng / ml, decreasing to 22.4 ± 5 at 24 h, 17.1 ± 3 at 72 h, and 6.8 ± 2 ng / ml at 168 h (Figure 6A). Although recovery of all sc injected DMFAT-PTX was technically difficult, analysis of drug residues at the injection site after 2 h showed 207 ± 14 μg / g (approximately 41% of the 500 μg / g injected dose). This concentration significantly decreased to 101 ± 11 (24 h), 13.2 ± 3 (48 h), and 5.2 ± 0.3 μg / gr at 72 h. At day 7, the IC 50 Thus, a local drug concentration of 1.14 ± 0.1 μg / gr of PTX was found to be pharmacologically significant (Figure 6B). In summary, these data are similar to those already reported using other mouse strains (6).
[0089] The kinetics of PTX release in the presence of tumors showed significant differences compared to normal mice. After 2 hours, PTX in the blood was about 90 ng / ml, and after 24 hours it had dropped to about 7 ng / ml, indicating that PTX was reduced more rapidly in the blood of tumor-bearing mice. In addition, at 72 hours, PTX in the blood was below detectable levels (Figure 6C). Two hours after injection, DMFAT-PTX implanted near the tumor nodule was still technically very difficult to fully recover, but the concentration of PTX in the remaining DMFAT-PTX was significantly reduced compared to that obtained from normal mice, at 86.58 μg / gr (only 17.3% of that initially injected), and the nearby tumor nodule was undetectable. In the tumor, PTX detection began after 24 hours. At this time point, we found that PTX was 3.35 ug / gr and 0.41 ug / gr in the remaining DMFAT and tumor, respectively. At 48 h, the PTX concentration decreased by about 50% (1.81 μg / gr) in the DMFAT, but increased 4-fold (1.6 μg / gr) in the tumor, thus reaching a PTX concentration almost equivalent to that in the adjacent DMFAT. Subsequent analyses performed on days 3 and 7 showed that the PTX concentrations in the tumor and in the adjacent DMFAT remained almost equivalent (Figure 6D). An overview of the dynamics of PTX concentrations in the tumor and in the adipose tissue is shown in Figures 6E and 6F. It should be noted that the local PTX concentrations present in both the DMFAT and the tumor on day 7 were 0.2 ± 0.08 and 0.30 ± 0.18 μg / gr, respectively, about one-fifth to one-third of the values recovered in normal mice (1.14 ± 0.1 ug / gr). However, both PTX concentrations were also significantly higher than the IC of PTX on Hep-3B cells. 50 (0.015μg / gr) was still higher.
[0090] In summary, these data appear to indicate that tumor nodules initially promoted PTX release from DMFAT when it was in close proximity. Equilibrium between PTX concentrations in DMFAT and tumors was nearly reached at about 48 h, and PTX concentrations were significantly detectable in tumors for at least 7 days; this concentration must be considered pharmacologically significant.
[0091] Consideration One of the main problems of systemic chemotherapy is its non-specificity, affecting both cancer cells and normal healthy cells, which leads to undesirable side effects (17, 18). Therefore, the development of novel chemotherapy approaches that can act preferentially at the tumor site is of great interest to improve the efficacy of anticancer drugs and the quality of life of cancer patients (19, 20). For this purpose, the authors of the present invention have already demonstrated that mesenchymal stromal cells (MSCs) could be an optimal tool for delivering anticancer drugs such as PTX and doxorubicin (14, 21, 22).
[0092] Given the optimal ability of MSCs to function as scaffold cells, and adipose tissue (AT) being the natural container for MSCs, it was hypothesized that lipoaspirate-derived MFAT would perform better for drug delivery, given its histological and structural scaffold-like characteristics (9, 10). The validity of this hypothesis was recently fully demonstrated by showing that both MFAT and DMFAT can take up and release PTX, and when DMFAT-PTX was placed in the tumor resection area, it could prevent or delay cancer recurrence (6).
[0093] To extend these results, we also investigated within the present invention whether a single treatment with DMFAT-PTX located close to the tumor mass was effective in inhibiting the growth of well-established primary HCC tumors in mice. HCC is a tumor that is considered to be less responsive to systemic therapy (23, 24, 25). The HCC characteristics of the Hep-3B cell line used here were first confirmed by histological analysis of tumor nodules formed after sc cell injection in nude mice.
[0094] Preliminary in vitro experiments to establish the sensitivity of He-3B cells to PTX inhibition showed that IC 50 (6, 14, 21). However, in vitro activity of MFAT and DMFAT loaded with various concentrations of PTX on Hep-3B cells showed that both PTX-loaded MFAT and DMFAT were equally effective in inhibiting Hep-3B proliferation, and either co-culture or CM was highly effective and PTX prestimulation dose-dependent. These results were similar to those previously observed using other cancer cell lines (6).
[0095] By using a 3D assay consisting of a mixture of Hep-3B cells and PTX-loaded or unloaded DMFAT specimens embedded in a Matrigel matrix to mimic the in vivo situation, we demonstrated that PTX released by DMFAT triggered strong cancer cell apoptosis that was directly proportional to the dose of PTX loaded. This apoptotic effect was also confirmed by analysis of Annexin V expression on Hep-3B, demonstrating that PTX is a cancer cell apoptosis inducer (26).
[0096] Although Hep-3B cells have been widely used in vivo to induce HCC tumors (27), we performed preliminary experiments to establish the dose of Hep-3B required to obtain 100% tumor elimination and the timing to obtain palpable tumors (mass approx. 100 mg) of 0.5-0.7 cm in diameter in all mice. When the tumor appeared as a clearly palpable mass, DMFAT specimens loaded with or without PTX were placed as close as possible to the cancer nodule. In this regard, the optimal treatment route, intratumoral type injection, was considered to be the most suitable for smaller tumor volumes (100-150 mm). 3 ) with DMFAT 200μl (200mm 3 This was not technically feasible, due to the inability to inject 100 mg / kg of PTX in 1 ml of DMFAT. The PTX dose of 10 mg / kg initially used in this study was based on our previous work, which is close to the maximum drug concentration that can be loaded in 1 ml of DMFAT, and was also based on human clinical studies (6, 28). DMFAT-PTX treatment resulted in strong tumor growth inhibition; tumor mass was about 1 g at day 60, whereas in mice treated with either control or free PTX or DMFAT, the same tumor mass was reached only after 24–31 days, with a maximum of 2 g at about 29–36 days. In addition, 33% of mice treated with DMFAT-PTX were tumor-free 90 days after implantation, as confirmed by histological examination of the skin area.
[0097] In particular, the high dose of PTX delivered by DMFAT caused an undesirable effect, with all mice developing skin ulcers at the tumor site accompanied by the formation of necrotic areas, which in all cases healed spontaneously without drug treatment. Such an aspect was not observed in our previous study, in which DMFAT-PTX was placed in the tumor resection area or injected intraperitoneally (6). We believe that this undesirable side effect was caused by the high dose of PTX delivered and the efficient drug concentration of DMFAT, especially when located in the subcutaneous area. Whatever the reason, the results clearly demonstrated the effectiveness of DMFAT in suppressing the drug mainly at the injection site. This conclusion was also supported by the following observations: 1) local injection of free PTX agent at a similar high dose did not induce skin ulcers; 2) a reduction in the dose of DMFAT-loaded drug did not induce skin ulcers, but maintained antitumor activity.
[0098] Finally, we analyzed the PK of PTX released by DMFAT loaded with 5 mg / kg PTX in healthy and tumor-bearing mice. In summary, in normal mice, DMFAT retained most of the PTX at the local injection site, and blood PTX concentrations declined rapidly, showing PK similar to that previously observed using various healthy mouse strains (6). Instead, PTX delivered by DMFAT in tumor-bearing mice appeared to have variable PK. We noted that blood PTX concentrations declined very rapidly; PTX was only detectable up to 24 h after subcutaneous DMFAT-PTX injection (up to 7 days in healthy mice). Although it is technically difficult to recover all the injected DMFAT-PTX, especially in tumor-bearing mice, an accelerated release of PTX was observed, especially early (2 h), in the remaining peritumoral adipose tissue. Only 14% of the total PTX initially injected was recovered (vs. 40% in normal mice). In adjacent tumors, PTX detection began at 24 h and remained detectable in both tissues for up to 7 days, with kinetics that reached drug concentration equilibrium between adipose and tumor tissues after 48 h. At this time point, PTX concentrations in tumors were above the IC50 , and was therefore consistent with the effects induced in vivo by DMFAT-PTX at the same 5 mg / kg dose.
[0099] In conclusion, the results presented here, taken together, strongly support the original hypothesis and extend previous results proposing that MFAT and its derived devitalized DMFAT counterpart are natural biomaterials capable of absorbing, transporting, and localizing chemotherapeutic drugs.
[0100] This approach has great advantages compared to other scaffolds (natural / synthetic) that could potentially be used in the oncology field (29-32). Indeed, as well as the easy availability of the material (adipose tissue is easily accessible from any patient by liposuction), the preparation of MFAT is rapid and carried out through a closed sterile system (Lipogems® device) that does not require GMP conditions for clinical use (8). Moreover, drug loading is a rapid procedure that can be performed in the same operating room during the cancer patient's surgery or prepared in advance and stored at -80 (DMFAT) before preferential autologous use.
[0101] Further studies are required to better understand the exact mechanism by which MFAT and DMFAT bind PTX (specifically, which lipid / protein components are involved) and how the drug is released as free drug or via extracellular vesicles (33). (References) TIFF2024542042000003.tif214166TIFF2024542042000004.tif230166TIFF2024542042000005.tif215166TIFF2024542042000006.tif64166
Claims
1. 1. A tissue-based drug delivery system for use in the treatment and / or prevention of liver cancer, preferably hepatocellular carcinoma, comprising: - Microfragmented adipose tissue (MFAT), preferably comprising clusters of adipose tissue having a size in the range of 10 to 5000 μm, preferably 100 to 3000 μm, more preferably 200 to 2500 μm, even more preferably 30 to 1500 μm, preferably 200 to 900 μm, more preferably 400 to 900 μm; and - At least one anticancer drug A tissue-based drug delivery system comprising:
2. 2. The tissue-based drug delivery system for use according to claim 1, wherein the MFAT is non-enzymatically microfragmented adipose tissue.
3. 3. The tissue-based drug delivery system for use according to claim 1 or 2, wherein the MFAT is devitalized microfragmented adipose tissue (DMFAT).
4. The tissue-based drug delivery system for use according to any one of claims 1 to 3, wherein the adipose tissue is isolated from a mammal, more preferably from a human, said human being being alive or dead.
5. 5. The tissue-based drug delivery system for use according to any one of claims 1 to 4, wherein the adipose tissue is of autologous or xenogeneic origin.
6. The anticancer drug may be paclitaxel, docetaxel, lenvatenib, gemcitabine, mitomycin C, or vinorelbine, vincristine, vinblastine, nocodazole, epothilone, and navelbine, teniposide, actinomycin, amsacrine, anthracycline, bleomycin, busulfan, camptothecin, carboplatin, chlorambucil, cisplatin, cyclophosphamide, cytoxan, dactinomycin, daunorubicin, doxorubicin, epirubicin, hexamethylmelamine oxaliplatin, ifosfamide, melphalan, merchlorethamine, mitomycin, mitoxantrone, nitrile ...
6. The tissue-based drug delivery system for use according to any one of claims 1 to 5, selected from rosourea, plicamycin, procarbazine, teniposide, triethylenethiophosphoramide and etoposide (VP16), adriamycin, amsacrine, camptothecin, daunorubicin, dactinomycin, doxorubicin, eniposide, epirubicin, etoposide, idarubicin, irinotecan (CPT-11) and mitoxantrone, pemetrexed, 5-fluorouracil (5-FU), methotrexate, cyclophosphamide, bortezomib, tomozolomide, sorafenib, or any combination thereof.
7. The anticancer drug is - sorafenib and paclitaxel; or - cyclophosphamide and paclitaxel; or - Adriamycin and Paclitaxel 7. The tissue-based drug delivery system for use according to claim 6, which is a combination of:
8. The tissue-based drug delivery system for use according to claim 6 or 7, wherein the amount of the anti-cancer drug is in the range of 0.1 to 1 mg per ml of MFAT or DMFAT.
9. 9. The tissue-based drug delivery system for use according to any one of claims 1 to 8, wherein the tissue-based drug delivery system is injected locally into a tumor tissue site and releases a therapeutically effective amount of the anti-cancer drug in situ.
10. 10. The tissue-based drug delivery system for use according to claim 9, wherein the anticancer drug is paclitaxel.
11. The tissue-based drug delivery system for use according to any one of claims 1 to 10, wherein the cancer is primary liver cancer or metastatic liver cancer, preferably primary or metastatic hepatocellular carcinoma.
12. 12. A tissue-based drug delivery system for use according to any one of claims 1 to 11 in combination with a further therapeutic treatment.
13. A pharmaceutical formulation for use in the treatment and / or prevention of liver cancer, preferably hepatocellular carcinoma, comprising a tissue-based drug delivery system according to any one of claims 1 to 12 and a pharma- ceutical acceptable vehicle or excipient.
Citation Information
Patent Citations
Device and method for preparing tissue, particularly adipose tissue, for transplantation from lobular fat extracted by liposuction
WO2011145075A2
Drug delivery system
WO2018193413A1
